Prior to the creation of Preora, Vadim Backman’s Northwestern University laboratory had received close to $20 million in NIH and NSF grant funding for the development of the core PWS technology, and an additional $6.9 million in fast track SBIR/STTR grants to support the product and process development for commercialization. The extraordinarily high level of grant funding serves as evidence of the clinical potential of the PWS technology platform.
The company is planning to initiate a Series A raise in Q4 2017. The funds will be used to complete the pivotal clinical studies for the lung test, gain CLIA lab certification, initiate clinical validation studies for the colorectal cancer test and support the launch of the lung cancer test.
Please contact John Hart, President and CEO, at firstname.lastname@example.org to indicate interest or learn more about investment opportunities.